California-based Azalea Therapeutics, a biotech promising to redefine precision genomic medicines in vivo, has announced its ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Genetically modified organisms, also known as GMOs, have been a hot topic of conversation among researchers, producers, ...

We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

Learn why research that continues to look for new substrate alternatives is essential to the future of growing.

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

According to Nova One Advisor, the global gene editing market size is calculated at USD 11.29 billion in 2025 and is expected ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a ...